alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 70.25 Labeling requirements for color additives (other than hair dyes). ( a ) *General labeling requirements.* All color additives shall be labeled with sufficient information to assure their safe use and to allow a determination of compliance with any limitations imposed by this part and parts 71, 73, 74, 80, and 81 of this chapter. In addition to all other information required by the act, labels for color additives, except those in a form suitable for coloring the human body, shall state: ( 1 ) The name of the straight color or the name of each ingredient comprising the color additive, if it is a mixture.
( 2 ) A statement indicating general limitations for the use of the color additive, such as “for food use only”; “for food, drug, and cosmetic use”; “for use in drugs for external application only.”
( 3 ) Where regulations issued impose quantitative limitations for a general or specific use of a straight color, the amount of each such straight color in terms of weight per unit/volume or percent by weight.
( 4 ) An expiration date if stability data require it.
( b ) *Special labeling for color additives with tolerances.* Where tolerances are imposed for a general or specific use of a color additive, the label shall in addition provide directions for use of the color additive which if followed will preclude the food, drug, or cosmetic to which it is added from containing an amount of the color additive in excess of the tolerance.
( c ) *Special labeling for color additives with other limitations.* If use of the color additive is subject to other limitations prescribed in this part, such limitations shall be stated on the label of the color additive by a plain and conspicuous statement. Examples of such limitation statements are: “Do not use in products used in the area of the eye”; “Do not use for coloring drugs for injection.”
( d ) *Special labeling for color additives not exempt from certification.* Color additives not exempt from the certification procedures shall in addition include in the labeling the lot number assigned by the Color Certification Branch, except that in the case of any mixture for household use which contains not more than 15 percent of pure color and which is in packages containing not more than 3 ounces there appears on the label, a code number which the manufacturer has identified with the lot number by giving to the Food and Drug Administration written notice that such code number will be used in lieu of the lot number.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1420 Coronary artery disease risk indicator using acoustic heart signals. ( a ) *Identification.* A coronary artery disease risk indicator using acoustic heart signals is a device that records heart sounds including murmurs and vibrations to calculate a patient-specific risk of presence of coronary artery disease, as an aid in cardiac analysis and diagnosis.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must fulfill the following: ( i ) Testing must include a discussion of the patient population and any statistical techniques used for analyzing the data; and
( ii ) Testing must be representative of the intended use population for the device. Any selection criteria or sample limitations must be fully described and justified.
( 2 ) Acoustic performance testing must evaluate microphone sensitivity, sound acquisition bandwidth, and amplitude accuracy. The acoustic sensor specifications and mechanism used to capture heart sounds must be described.
( 3 ) A scientific justification for the validity of the algorithm(s) must be provided. This justification must fulfill the following: ( i ) All inputs and outputs of the algorithm must be fully described;
( ii ) The procedure for segmenting, characterizing, and classifying the acoustic signal must be fully described; and
( iii ) This justification must include verification of the algorithm calculations and validation using an independent data set.
( 4 ) The patient-contacting components of the device must be demonstrated to be biocompatible.
( 5 ) Software verification, validation, and hazard analysis must be performed.
( 6 ) Human factors/usability testing must demonstrate that the user can correctly use the device, including device placement, based solely on reading the directions for use.
( 7 ) Performance data must demonstrate the electromagnetic compatibility and electrical safety of the device.
( 8 ) Labeling must include the following: ( i ) A description of what the device measures and outputs to the user;
( ii ) Instructions for proper placement of the device;
( iii ) Instructions on care and cleaning of the device;
( iv ) Warnings identifying sensor acquisition factors that may impact measurement results and instructions for mitigating these factors; and
( v ) The expected performance of the device for all intended use populations and environments.
[87 FR 32990, June 1, 2022]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1495 Magnesium test system. ( a ) *Identification.* A magnesium test system is a device intended to measure magnesium levels in serum and plasma. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium).
( b ) *Classification.* Class I.
<TABLE> <S> <C>

<ARTICLE>     7
<MULTIPLIER>     1,000,000

       
<S>                                            <C>
<PERIOD-TYPE>                                  YEAR
<FISCAL-YEAR-END>                              DEC-31-1996
<PERIOD-END>                                   DEC-31-1996
<DEBT-HELD-FOR-SALE>                           13,572
<DEBT-CARRYING-VALUE>                          0
<DEBT-MARKET-VALUE>                            0
<EQUITIES>                                     2,303
<MORTGAGE>                                     0
<REAL-ESTATE>                                  0
<TOTAL-INVEST>                                 16,479
<CASH>                                         377
<RECOVER-REINSURE>                             2,358
<DEFERRED-ACQUISITION>                         495
<TOTAL-ASSETS>                                 25,388
<POLICY-LOSSES>                                13,343
<UNEARNED-PREMIUMS>                            1,170
<POLICY-OTHER>                                 0
<POLICY-HOLDER-FUNDS>                          1,836
<NOTES-PAYABLE>                                556
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    150
<COMMON>                                       5
<OTHER-SE>                                     4,605
<TOTAL-LIABILITY-AND-EQUITY>                   25,388
<PREMIUMS>                                     4,648
<INVESTMENT-INCOME>                            837
<INVESTMENT-GAINS>                             223
<OTHER-INCOME>                                 43
<BENEFITS>                                     3,373
<UNDERWRITING-AMORTIZATION>                    1,106
<UNDERWRITING-OTHER>                           492
<INCOME-PRETAX>                                780
<INCOME-TAX>                                   213
<INCOME-CONTINUING>                            567
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   567
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
<RESERVE-OPEN>                                 9351
<PROVISION-CURRENT>                            2763
<PROVISION-PRIOR>                              106
<PAYMENTS-CURRENT>                             485
<PAYMENTS-PRIOR>                               1990
<RESERVE-CLOSE>                                9458
<CUMULATIVE-DEFICIENCY>                        (159)
        

</TABLE>
(logo)WELLS FARGO         **CommercialMortgage Servicing**

                                               D1050-084, 8th Floor 

401 South TryonStreet

Charlotte, NC 28202

1-800-326-1334

 

 

**ANNUAL STATEMENT OF COMPLIANCE**

 

ReferenceisherebymadetothatcertainPooling and Servicing Agreement dated as of May 1, 2015, by and among CREDITSUISSE FIRST BOSTONMORTGAGESECURITIES CORP., as Depositor, WELLS FARGO BANK, NATIONAL ASSOCIATION, asMaster Servicer, RIALTO CAPITAL ADVISORS, LLC, as Special Servicer, PARK BRIDGELENDERSERVICES LLC, as OperatingAdvisor, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Certificate Adminstrator,and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee, with respect toCommercial Mortgage Pass-Through Certificates, Series 2015-C2 (the"Agreement"). Capitalized terms used herein not otherwise definedshall have the meanings assigned in the Agreement.

 

Pursuantto Section 10.07 of this Agreement, I, Daniel Bober, Executive Vice Presidentof Commercial Mortgage Services do hereby certify that:

 

1. Areview of the activities of the Master Servicer during the period from January1, 2017 through December 31, 2017 (the “Reporting Period”), and of itsperformance per the Agreement during such period has been made under mysupervision,and

 

2. To the best of my knowledge, basedon such review, the Master Servicer, has fulfilled all of its obligations underthis Agreement in all material respects throughout the ReportingPeriod.

 

 

IN WITNESS WHEREOF, the undersigned hasexecuted this Certificate as of the 28th day ofFebruary2018.

 

 

/s/ Daniel Bober

Daniel Bober

Executive Vice President 

Wells Fargo Bank

 

 

WellsFargo Bank,N.A                                                                         (logo)Together we’ll go far
**EXHIBIT
      32.2**


SECTION
      1350 CERTIFICATION





I,
      Edward P. Smolyansky, certify, pursuant to 18 U.S.C. Section 1350, as
      adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the
      Quarterly Report of Lifeway Foods, Inc. (the “Company”) on Form 10-QSB for nine
      month period ended September 30, 2007:





(1)
      Fully complies with the requirements of section 13(a) or 15(d) of the Securities
      Exchange Act of 1934; and





(2)
      that the information contained in the report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.





This
      written statement is being furnished to the Securities and Exchange Commission
      as an exhibit to such Form 10-QSB. A signed original of this written statement
      required by Section 906 has been provided to the Company and will be
      retained by the Company and furnished to the Securities and Exchange Commission
      or its staff upon request.





Date:
                  November 14, 2007
            /s/
                Edward P. SmolyanskyChief
                Financial and Accounting Officerand
                Treasurer
<PAGE>
                                                                    Exhibit 23.1


            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (File Nos. 333-53374, 333-105963 and 333-127025) and Form
S-3 (File Nos. 333-106126, 333-117264, 333-119864 and 333-128074) of Evergreen
Solar, Inc. of our report dated March 16, 2006 relating to the financial
statements, financial statement schedule, management's assessment of the
effectiveness of internal control over financial reporting and the effectiveness
of internal control over financial reporting, which appears in this Form 10-K.


/s/ PricewaterhouseCoopers LLP

Boston, MA
March 16, 2006
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED  FROM  THE BALANCE
SHEET AS OF JUNE 30, 1999 AND FROM THE  STATEMENT  OF  OPERATIONS  FOR  THE  SIX
MONTHS ENDED JUNE 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1999
<PERIOD-END>                                   JUN-30-1999
<CASH>                                         480,918
<SECURITIES>                                   0
<RECEIVABLES>                                  15,380
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               0<F1>
<PP&E>                                         9,781,186
<DEPRECIATION>                                 0<F2>
<TOTAL-ASSETS>                                 10,470,935
<CURRENT-LIABILITIES>                          0<F1>
<BONDS>                                        4,973,026
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     5,326,633
<TOTAL-LIABILITY-AND-EQUITY>                   10,470,935
<SALES>                                        946,001
<TOTAL-REVENUES>                               958,544
<CGS>                                          0
<TOTAL-COSTS>                                  745,040
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             191,427
<INCOME-PRETAX>                                22,077
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            22,077
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   22,077
<EPS-BASIC>                                  0
<EPS-DILUTED>                                  0
<FN>
<F1> THE PARTNERSHIP HAS AN UNCLASSIFIED BALANCE SHEET, THEREFORE THE BALANCE IS
$0.
<F2> THIS INFORMATION IS NOT DISCLOSED  IN  THE  PARTNERSHIP'S FORM 10-Q FILING.
</FN>



</TABLE>
# C_2014245EN.01001702.xml

| 28.7.2014 | EN | Official Journal of the European Union | C 245/17 |
| --- | --- | --- | --- |

28.7.2014

EN

Official Journal of the European Union

C 245/17

---

Action brought on 11 April 2014 — CBM Creative Brands Marken v OHIM — Aeronautica Militare — Stato Maggiore (Trecolore)

(Case T-227/14)

2014/C 245/24

Language in which the application was lodged: English

Parties

Parties

Applicant: CBM Creative Brands Marken GmbH (Zürich, Switzerland) (represented by: U. Lüken, M. Grundmann and N. Kerger, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Aeronautica Militare — Stato Maggiore (Rome, Italy)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 29 January 2014 in Case R 253/2013-1 in so far as the First Board of Appeal annuls the decision of the Opposition Division and upholds the opposition against the application mark rejecting the application No 009 877 325 in regard of the goods in classes 18 and 25; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 29 January 2014 in Case R 253/2013-1 in so far as the First Board of Appeal annuls the decision of the Opposition Division and upholds the opposition against the application mark rejecting the application No 009 877 325 in regard of the goods in classes 18 and 25;

| — | Dismiss the opposition against Application No 009 877 325 in its entirety; |
| --- | --- |

—

Dismiss the opposition against Application No 009 877 325 in its entirety;

| — | Order OHIM to pay the costs. |
| --- | --- |

—

Order OHIM to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: The word mark ‘Trecolore’ for goods and services in Classes 18, 25 and 35 — Community trade mark application No 9 877 325

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: Aeronautica Militare — Stato Maggiore

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: The community and national word and figurative mark ‘FRECCE TRICOLORI’, for goods and services in Classes 9, 14, 16, 18, 20, 25, 28 and 41

Mark or sign cited in opposition:

Decision of the Opposition Division: Rejected the opposition in its entirety

Decision of the Opposition Division:

Decision of the Board of Appeal: Annulled the contested decision in part

Decision of the Board of Appeal:

Pleas in law: Infringement of articles 8(1)(b) and 8(5) of Regulation No 207/2009

Pleas in law:

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3980 Respiratory viral panel multiplex nucleic acid assay. ( a ) *Identification.* A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses: ( 1 ) Influenza A and Influenza B;
( 2 ) Influenza A subtype H1 and Influenza A subtype H3;
( 3 ) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B;
( 4 ) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus;
( 5 ) Human Metapneumovirus;
( 6 ) Rhinovirus; and
( 7 ) Adenovirus.
( b ) *Classification.* Class II (special controls). The special controls are: ( 1 ) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;”
( 2 ) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and
( 3 ) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents.
[74 FR 52138, Oct. 9, 2009]
Order entered October 22, 2020

In t he 

### Court of Appeals Fifth District of Texas at Dallas No. 05 - 19 - 01515 - CR No. 05 - 19 - 0151 7 - CR No. 05 - 19 - 0151 8 - CR No. 05 - 19 - 0151 9 - CR No. 05 - 19 - 015 44 - CR No. 05 - 19 - 015 4 6 - CR JIMMY DUANE TUCKER, Appellant

V. THE STATE OF TEXAS, Appellee On Appeal from the 366th Judicial District Court

Collin County, Texas Trial Court Cause No s . 366 - 84179 - 2017 & 366 - 84425 - 2019 ORDER We GRANT the State ’ s October 21, 2020 motion for an extension of time to file its brief in these appeals and ORDER the brief received with the motion filed as of the date of this order.

/s/ CORY L. CARLYLE JUSTICE
<PAGE>



                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                               ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES--OXLEY ACT OF 2002


         In connection with the Quarterly Report of GVC Venture Corp. (the
"Company") on Form 10-QSB for the period ended September 30, 2002 as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), I,
Marc Hanover, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss. 1350, adopted pursuant to Section 906 of the Sarbanes--Oxley Act of
2002 that to my knowledge:

         (1)   The Report fully complies with the requirements of Section 13(a)
               of the Securities Exchange Act of 1934; and

         (2)   The information contained in the Report fairly presents, in all
               material respects, the financial condition and results of
               operations of the Company.



                                            /s/ Russel Banks
                                            ----------------------------------
                                            Russel Banks
                                            Chairman of the Board of Directors
                                            (Principal Executive Officer)


Date: November 12, 2002
# C_2014253EN.01005201.xml

| 4.8.2014 | EN | Official Journal of the European Union | C 253/52 |
| --- | --- | --- | --- |

4.8.2014

EN

Official Journal of the European Union

C 253/52

---

Action brought on 10 June 2014 — Promoinmo v Commission

(Case T-406/14)

2014/C 253/68

Language of the case: Spanish

Parties

Parties

Applicant: Promoinmo, SL (Barcelona, Spain) (represented by: A. López Gómez, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | in the alternative, annul the decision categorising the measures which together constitute the ‘Spanish Tax Lease System’ (‘STLS’) as new State aid that is incompatible with the internal market; |
| --- | --- |

—

in the alternative, annul the decision categorising the measures which together constitute the ‘Spanish Tax Lease System’ (‘STLS’) as new State aid that is incompatible with the internal market;

| — | in the alternative, annul Articles 1 and 4 of the contested decision, which identify the investors in the Economic Interest Groupings (EIGs) as the only beneficiaries of the alleged aid and, consequently, as solely liable for its recovery; |
| --- | --- |

—

in the alternative, annul Articles 1 and 4 of the contested decision, which identify the investors in the Economic Interest Groupings (EIGs) as the only beneficiaries of the alleged aid and, consequently, as solely liable for its recovery;

| — | in the alternative, annul Article 4 of the contested decision, in so far as it orders recovery of the alleged aid in breach of general principles of EU law; |
| --- | --- |

—

in the alternative, annul Article 4 of the contested decision, in so far as it orders recovery of the alleged aid in breach of general principles of EU law;

| — | in the alternative, annul Article 4 of the contested decision, in so far as it makes a determination as to the lawfulness of private contracts between the investors and other entities; and |
| --- | --- |

—

in the alternative, annul Article 4 of the contested decision, in so far as it makes a determination as to the lawfulness of private contracts between the investors and other entities; and

| — | order the Commission to pay the costs of these proceedings. |
| --- | --- |

—

order the Commission to pay the costs of these proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments are those raised in Case T-401/14 Duro Felguera SA v Commission.

Duro Felguera SA

Commission

---